Viatris Raises 2026 Guidance After Strong Q2, Despite Manufacturing Disruptions
The generics and specialty drugmaker reported 3.5% revenue growth and lifted full-year targets, even as it addresses FDA inspection observations at a key facility.
Strong Quarter Drives Guidance Raise
Viatris Inc. reported second-quarter revenues of $3.8 billion, representing 3.5% operational growth year-over-year, and raised its full-year 2026 financial guidance across all key metrics following better-than-expected performance in the first half (earnings call, 2026-08-06).
The pharmaceutical company posted adjusted EBITDA of $1.2 billion and adjusted earnings per share of $0.69 for the quarter. CEO Scott Smith said the results "exceeded our expectations and reflect the strong momentum across our businesses and continued improvement in operating leverage" (earnings call, 2026-08-06).
Greater China and Complex Generics Lead Growth
Greater China delivered another standout quarter with net sales increasing 16% year-over-year, driven by favorable market fundamentals including an aging population and demand for cardiovascular products. E-commerce sales in the region surged 36% versus the prior year (earnings call, 2026-08-06).
In North America, net sales grew 1%, led by complex generics and transdermal products, including estradiol patches and complex injectables such as octreotide and iron sucrose. Developed markets overall saw net sales increase 2% versus the prior year (earnings call, 2026-08-06).
Adjusted gross margin improved nearly 1 percentage point to 57.5%, driven primarily by the strong Greater China performance and favorable product mix in North American generics (earnings call, 2026-08-06).
Manufacturing Headwinds Acknowledged
The company's updated outlook incorporates "certain intermittent manufacturing disruptions" at its Nashik facility following a fire and an FDA inspection in May 2026. Smith said Viatris is "communicating with the FDA, working closely with external experts and have initiated a comprehensive remediation plan to address the inspection observations" (earnings call, 2026-08-06).
Pipeline Advances and Strategic Shifts
Viatris announced FDA approval for Winland, a once-weekly transdermal hormonal contraceptive patch, ahead of its target date, with a launch planned for later this year. Chief R&D Officer Philippe Martin highlighted that the approved label reflects efficacy in women with a BMI of 25 to less than 30 kg/m² with no BMI-based limitation for this population (earnings call, 2026-08-06).
The company reported positive Phase III results for Nefecon in Japan for primary IgA nephropathy and expects to submit a new drug application by year-end 2026. Regulatory decisions for pitolisant for excessive daytime sleepiness are anticipated in the second half of 2026 (earnings call, 2026-08-06).
Phase III programs for cenerimod and chelation remain on track with readouts expected in the first half of 2027, which Smith described as "meaningful long-term blockbuster growth opportunities" if successful (earnings call, 2026-08-06).
In a strategic shift, Viatris agreed to sell global rights to an eye care product (turbid), "reflecting a strategic shift away from eye care as a therapeutic area of focus" (earnings call, 2026-08-06).
Capital Allocation
The company has returned approximately $550 million to shareholders year-to-date through dividends and share repurchases, supported by strong cash generation and proceeds from monetizing its Biocon equity stake. MarginX data shows a $0.12 cash dividend scheduled for August 21, 2026, with the next earnings report expected November 6, 2026.
This article was generated by MarginX from the earnings call on 2026-08-06. It is not investment advice.